Jeffrey Farma MD FACS

Dr Walker Lyons @foxchasesurgonc.bsky.social presenting his work on sentinel nodes and #breastcancer @socsurgonc.bsky.social #SSO2025 @bctrials.bsky.social

Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.

Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies
@karmanoscancer.bsky.social #crcsm #pancsm #Oncology
www.onclive.com/view/data-co...

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma @mdanderson.bsky.social #oncology #sarcoma #MedEd www.onclive.com/view/biomark...

New 2025 NAPRC Standards Highlight Advances in Rectal Cancer Care The evolution of rectal cancer care, including the rise of patients assigned to “watch and wait” protocols, will be included in the new standards.

Learn more about the new National Accreditation Program for Rectal Cancer standards released by the @facs.org in 2025 that address recent advancements in rectal cancer care.

Heading to #SSO2025 @socsurgonc.bsky.social remember to RSVP for NCI Alumni Reception to honor Dr Rosenberg

#Philadelphia #Surgery @foxchasesurgonc.bsky.social representing at #ASC2025 #LasVegas @academicsurgery.bsky.social @universitysurgeons.bsky.social

Fox Chase Cancer Center Researchers Review Guidelines for Therapies Given to Melanoma Patients Before and After Initial Treatment A team of colleagues at Fox Chase Cancer Center recently published an updated review of guidelines governing the use of neoadjuvant and adjuvant therapy for patients with melanoma.

Fox Chase Cancer Center Researchers Review Guidelines for Therapies Given to Melanoma Patients Before and After Initial Treatment
@foxchasesurgonc.bsky.social @jeffreyfarma.bsky.social #melsm #oncology
www.onclive.com/view/fox-cha...

Great to see so many presentations from our students and residents @foxchasesurgonc.bsky.social #Asc2025 @academicsurgery.bsky.social @univsurg.bsky.social

SSO staff welcomed our incoming President, Dr. Russ Berman, to set SSO up for success during his 2025-2026 Presidency. We look forward to the productive year ahead!

Discover the progress and potential of cancer vaccines for solid tumors in this comprehensive review, highlighting historic trials and strategies for improved efficacy. Read more in @annsurgoncology.bsky.social surgonc.org/annals-of-su... #FeaturedArticle

The PIECE Trial explores the potential of adjuvant S-1 following neoadjuvant chemotherapy and surgery for esophageal squamous cell carcinoma. Promising results with a manageable safety profile! Read more in
@annsurgoncology.bsky.social: ow.ly/rAFO50UMRfe #FeaturedArticle

The Trump admin has cancelled the panels that approve NIH grants, & is also banning scientists from communicating with the public, attending conferences, and hiring.

NIH is the largest funder of biomedical research in the world. This will severely halt the development of many lifesaving treatments.

Honored to host Dr Carol Swallow today for our 2025 Paul J. Grotzinger lecture @foxchasesurgonc.bsky.social #sarcoma @curesarcoma.bsky.social @sarcoma.bsky.social

Great talk last night at Philadelphia Academy of Surgery with Dr Neha Goel on #breastcancer #disparity #epigenetic research @foxchasesurgonc.bsky.social @mskcancercenter.bsky.social

Congratulations to Dr Alycia So @foxchasesurgonc.bsky.social on being inducted last night to the Philadelphia Academy of Surgery

Fox Chase Cancer Center oncologist talks personalized medicine for pancreatic cancer There's no routine screening test for pancreatic cancer, and symptoms can be mistaken for common illnesses.

www.inquirer.com/health/fox-c... @foxchasesurgonc.bsky.social @pancan.bsky.social #pancreaticcancer @amcollsurgeons.bsky.social

JCI Insight - The financial impact of MD-PhD training compared with MD training for academic physicians

insight.jci.org/articles/vie...

Honored to receive the City and State Pennsylvania Impact Award @foxchasesurgonc.bsky.social @americansurgeon.bsky.social

Fox Chase Cancer Center oncologist talks personalized medicine for pancreatic cancer There's no routine screening test for pancreatic cancer, and symptoms can be mistaken for common illnesses.

www.inquirer.com/health/fox-c... @foxchasesurgonc.bsky.social @pancan.bsky.social #pancreaticcancer @amcollsurgeons.bsky.social

Periarterial Divestment and Triangle Clearance in Pancreatic Cancer: A Video Vignette - Annals of Surgical Oncology Annals of Surgical Oncology -

Periarterial Divestment and Triangle Clearance in Pancreatic Cancer: A Video Vignette ⁦‪@AnnSurgOncol‬⁩

link.springer.com/article/10.1...

Triphasic Learning Curve of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy - Annals of Surgical Oncology Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS–HIPEC) is an effective but costly procedure for select patients with peritoneal malignancies. The impact of progres...

Triphasic Learning Curve of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy ( #CRSHIPEC ) @FabianJohnston

rdcu.be/d1ar8

link.springer.com/article/10.1...

Clinical Outcomes, Costs, and Value of Surgery Among Older Patients with Colon Cancer at US News and World Report Ranked Versus Unranked Hospitals - Annals of Surgical Oncology Background US News and World Report (USNWR) hospital rankings influence patient choice of hospital, but their association with surgical outcomes remains ill-defined. We sought to characterize clinical...

Clinical Outcomes, Costs, and Value of Surgery Among Older Patients with #ColonCancer at US News and World Report Ranked Versus Unranked Hospitals

link.springer.com/article/10.1...

Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion - World Journal of Surgical Oncology Purpose This study aimed to develop postsurgical progression/hyperprogression recurrence (type III-IV recurrence) prediction models for hepatocellular carcinoma (HCC) patients with macroscopic vascular invasion (MaVI) and to guide treatment strategies in the accurate healthcare era. Patients and methods 393 HCC patients with MaVI from two central hospitals made up the entire study population. In developmental (290 patients) and validation (103 patients) cohorts, all patients were randomized into one or the other. Two prediction models for type III-IV recurrence were developed, based on the findings of univariate and multivariate analysis in the development cohort, and multidimensional verification was carried out in both cohorts. Results The postoperative recurrence rate of type III-IV in 393 HCC patients with MaVI was 70.9%. Young age, large tumor size (≥ 10 cm), node number, incomplete tumor capsule, postoperative complications, and high Ki67 index were the independent risk factors for relapse of type III-IV. In the development cohort, two nomograms (pre- and postoperative) had the Area Under the ROC curve (AUC) of 0.827 and 0.891, respectively. The two nomograms performed well, according to multidimensional verification methods such as clinical impact curves, decision curve analysis (DCA), and calibration curves. The validation cohort saw similar encouraging results. Both nomograms could separate patients into two distinct prognosis subgroups with ideal cutoff values of 170.3 presurgery and 175.0 postsurgery (both P < 0.05). Conclusion We constructed two novel and potentially clinically valuable models for predicting type III-IV recurrence. These two models can develop strategies for treating those suffering from HCC with MaVI owing to their strong prediction performance and availability.

Two predictive models for HCC recurrence developed successfully

by Huang Y, Su Y (...) Qi L et 6 al. in World J Surg Oncol #Surgery #SurgSky #GeneralSurgery #MedSky

🪡 read our summary here
📖 read the article:

#PancreaticCancer research starter pack.
65 of 150. Room for 85 more on this 1st starter pack.
Who did I miss?
go.bsky.app/FDafAW

Gun Violence is a Public Health Crisis.

#HPBsky

Hola Uruguay 🇺🇾☀️🌊 thank you for having me during the @amcollsurgeons.bsky.social session to talk about #pancreas #surgery and #cancer

Hasta pronto!

#MedSky #PancreasSky #HPBSky #SurgSky

The Quality of Evidence Supporting Clinical Practice Guidelines in General Surgery This meta-analysis assesses the strength and quality of clinical recommendations in practice guidelines published by professional societies.

Evidence is too often thin in general surgery: a call to generate more & better science to support clinical decisionmaking from @ucsfsurgery.bsky.social authors! @ucsfhealth.bsky.social @ucsfcancer.bsky.social @hannahdeckermd.bsky.social #SurgSky #MedSky jamanetwork.com/journals/jam...

Yes, it’s only Tuesday.

Newly Diagnosed with Skin Cancer Accurate, up-to-date information, answers, advice and support resources to help people who are newly diagnosed with skin cancer.

Newly diagnosed with #skincancer? Get medically-reviewed information, guidance and support www.skincancer.org/skin-cancer-...

Skin Cancer Information Discover what causes cancers of the skin; learn the signs & symptoms that you should never ignore. Skin cancer information you can trust.

Skin cancer 101: What you need to know. www.skincancer.org/skin-cancer-...